(Total Views: 1728)
Posted On: 11/04/2023 1:03:00 PM
Post# of 156681
Re: LateToLearn #138726
Just thought I’d share In response to the partnership discussions.
Let me share a quote from CytoDyn that supports my belief in a potential partnership:
"The Company has already been working toward decisions that create opportunities for partnerships... strategies that are time- and cost-effective and create the opportunity for non-dilutive financing such as license agreements, co-development, partnerships, etc." Where does it say we need more data?
Additionally, consider the perspective of Cyrus. In his last interview in July, he reiterated the Company's strategy to explore partnerships and its determination to maximize value through collaborations.
“In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect. I think that most companies are data-first,” he said. “If we come and we show the data THAT WE HAVE…I think they’ll see, here's an organization that has transformed from what it used to be”
We have the data.
Let me share a quote from CytoDyn that supports my belief in a potential partnership:
"The Company has already been working toward decisions that create opportunities for partnerships... strategies that are time- and cost-effective and create the opportunity for non-dilutive financing such as license agreements, co-development, partnerships, etc." Where does it say we need more data?
Additionally, consider the perspective of Cyrus. In his last interview in July, he reiterated the Company's strategy to explore partnerships and its determination to maximize value through collaborations.
“In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect. I think that most companies are data-first,” he said. “If we come and we show the data THAT WE HAVE…I think they’ll see, here's an organization that has transformed from what it used to be”
We have the data.


Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol

https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com

The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).



whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……